Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), and Abeome Corporation, a monoclonal antibody discovery and development company, have entered into a worldwide licensing agreement in which Molecular Templates has licensed a high affinity antibody directed to PD-L1 and […]
Athens, Georgia, April 19, 2017 – Abeome Corporation announced today that it has signed a Research Collaboration Agreement (RCA) with Centers for Disease Control and Prevention (CDC) for the identification of novel antibodies binding to the Zika virus using Abeome’s proprietary AbeoMouseTM platform. “We are very pleased to collaborate with the CDC using our proprietary antibody […]
Athens, Georgia, February 3, 2017 – Abeome Corporation will present 2 posters at Keystone February 13-16, 2017 describing significant advancements in its IL-25 asthma program. For more information see: Keystone_IL25_Abeome_3026 and: Keystone_IL25_Abeome_1005
Abeome Corporation announced today that it has received notification from the National Institute of Health – National Heart, Blood and Lung Institute of an award granting $1,482,472 over two years for the further development of proprietary monoclonal antibodies in Abeome’s portfolio.
Abeome Corporation announced today it has been named a Georgia Bio Innovation Award Winner.
Abeome Corporation announced today the closing of a $2M Angel Round.
Abeome announces a new website and brand refresh.
Abeome Corporation announced today the receipt of an award letter for a Small Business Innovative Research (SBIR) grant in the amount of $217,860 over 10 months.
Abeome Corporation announced today the receipt of an award letter for a Small Business Innovative Research (SBIR) grant in the amount of $275,916 over 10 months. The grant, titled “Semi-Targeted Immunotherapeutic Approach for Treatment of Obesity,” is a Phase 1 grant focused on generating a large number of monoclonal antibodies to human preadipocytes, the cells that are the precursors to fat cells.
Abeome has entered into a non-exclusive agreement with Enzo Life Sciences (NASDAQ: ENZO) to distribute core technology (DiSH™) and related growth media components in the form of kits to Enzo’s worldwide network of life science customers.